760
Participants
Start Date
November 1, 2025
Primary Completion Date
December 31, 2026
Study Completion Date
June 30, 2027
long-acting depot buprenorphine (LADB)
The intervention will measure patient-centered outcomes in people initiating LADB among a cohort of opioid-dependent PWID across sites in the seven project LMIC. Study participants will be enrolled from selected clinics that deliver routine opioid agonist maintenance treatment to PWID. The intervention will 1) Compare characteristics at baseline of those service clients who do and do not initiate LADB in relation to demographic characteristics, history of drug use, and outcomes; 2) Measure side effects and adverse events among those initiating LADB; and 3) Where appropriate, assess changes in outcomes between time of LADB initiation and 48 week follow-up, including HCV and HIV testing and treatment, quality of life, employment opportunities, and service preferences.
Collaborators (2)
UNITAID
OTHER
World Health Organization
OTHER
Médecins du Monde
OTHER
Frontline AIDS
OTHER
London School of Hygiene and Tropical Medicine
OTHER
International Network of People who Use Drugs
UNKNOWN
Monash University
OTHER
Population Services International
OTHER
Burnet Institute
OTHER
University of Bristol
OTHER
Alliance for the Public's Health
OTHER
Coact Technical Support Limited
UNKNOWN
PATH
OTHER